Clinical Trials Logo

Clinical Trial Summary

the study is a prospective, single-arm, open-label trial, designed to explore the efficacy and safety of Tumor-Treating Fields (TTFields) combined with second-line chemotherapy treatment in recurrent glioblastoma multiforme (GBM) , TTFields is an portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields


Clinical Trial Description

PAST CLINICAL EXPERIENCE: The effect of the electric fields generated by the TTFields has been tested in two Ⅲ phase trials in humans(EF-11&EF-14). The data from these trials suggest TTFields may improve time to disease progression and overall survival of recurrent GBM patients. EF-11 is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device.Although the number of patients in the trials is small, FDA has approved TTFields as a therapy for patients with recurrent GBM. DESCRIPTION OF THE TRIAL: Patients with GBM whose disease has recurred or progressed despite standard treatment (Surgery, radiation therapy, Temozolomide treatment) and meet all of the requirements for participation in the study will be included.Before receiving TTFields treatment, the patient can receive surgery again, and TTFields+BPC chemotherapy can be used after surgery; TTFields+BPC chemotherapy can also be used directly without surgery. During the trial, TTFields treatment is a cycle (treatment course) every four weeks, and patients are required to complete at least one cycle of treatment. Recommended average daily wearing time ≥18 hours, patients will need to return once every month the hospital outpatient clinics where they will be examined by a physician and undergo routine laboratory examinations. These routine visits will continue for as long as the patient's disease is not progressing. After progression, if such occurs, patients will need to return once per month for two more months to the outpatient clinic for similar follow up examinations. During the visits to the clinic patients will be examined physically and neurologically. A routine MRI of the head will be performed at baseline and after 2, 4 and 6 months. After this follow up plan, patients will be contacted once per month by telephone to answer basic questions about their health status. If the disease progresses, imaging tumor assessment or survival follow-up will be performed every 2 months thereafter, until 12 months of follow-up. The investigator will use the RANO evaluation criteria for tumor imaging assessment, and classify the objective tumor response as follows: The objective tumor response status based on the evaluation of the target lesion can be: complete response (CR), partial response (PR), stable disease ( SD), disease progression (PD). SCIENTIFIC BACKGROUND: Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet. Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (200 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating. The breakthrough finding made by NovoCure was that finely tuned alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are multiplying, TTFields cause the building blocks of these cells to move and pile up in such a way that the cells physically explode. In addition, cancer cells also contain miniature building blocks which act as tiny motors in moving essential parts of the cells from place to place. TTFields cause these tiny motors to fall apart since they have a special type of electric charge. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04689087
Study type Interventional
Source Sun Yat-sen University
Contact Qunying Yang
Phone 13802971439
Email Yangqy@sysucc.org.cn
Status Recruiting
Phase N/A
Start date April 1, 2020
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT00597493 - Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Phase 2
Completed NCT00379470 - Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Phase 3
Recruiting NCT01737346 - Procarbazine and Lomustine in Recurrent Glioblastoma Phase 2
Active, not recruiting NCT01464177 - Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00562419 - CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Phase 2
Completed NCT00071539 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors Phase 2
Active, not recruiting NCT02062827 - Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma Phase 1
Completed NCT00509301 - Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05868083 - The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma Phase 1
Completed NCT01576666 - Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Phase 2
Completed NCT00306618 - Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Phase 2
Completed NCT01934361 - Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Phase 1
Terminated NCT04915404 - Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Phase 1/Phase 2
Terminated NCT01756729 - Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Phase 4
Completed NCT00747253 - Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors Phase 1
Completed NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00481455 - Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Phase 2
Recruiting NCT03423628 - A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Phase 1